This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. This evidence concerns the gene IL23A and inflammatory bowel disease.